Peter Dorfmüller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter Dorfmüller has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Marc Humbert
INSERM UMR_S 999, Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Université Paris–Saclay , Le Kremlin Bicêtre
105 shared publications - David Montani
INSERM UMR_S 999 “Pulmonary Hypertension: Pathophysiology and Novel Therapies”, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
57 shared publications Elie Fadel
Paris-Saclay University, School of Medicine, Kremlin-Bicêtre, France; Surgical Research Lab; Department of Thoracic and Vascular Surgery and Heart‒Lung Transplantation, DHU Thorax Innovation, Marie Lannelongue Hospital, Le Plessis Robinson, France
40 shared publications- Frédéric Perros
Université Lyon 1, INSERM, INRAE, CarMeN Laboratory, 69310 Oullins-Pierre-Bénite, France
40 shared publications - Olivier Sitbon
Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
35 shared publications - Olaf Mercier
Department of Thoracic Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Universite' Paris-Saclay, Le Plessis-Robinson, France
31 shared publications
Latest Publications
- 7 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2601178
European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension
Background: Pulmonary arterial hypertension (PAH) is a severe, progressive disease of the small pulmonary arteries. These guidelines provide updated evidence-based recommendations for the treatment of PAH focusing on the latest scientific evidence on sotatercept, an activin signalling inhibitor targeting a novel pathway for the treatment of PAH, and on the role of right heart catheterisation (RHC) in the management of PAH patients during follow-up. Methods: A European Respiratory Society (ERS) Task Force, comprising global experts, methodologists and a patient representative, developed these clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Four PICO (Patients, Intervention, Comparator, Outcomes) questions and one narrative question have been addressed. Recommendations: The Task Force recommends add-on treatment with sotatercept in PAH patients who already receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death during follow-up; this recommendation is based on a high certainty of evidence available from randomised controlled trials (RCTs). In PAH patients at low risk of death, the Task Force does not provide a recommendation due to the low certainty of evidence and the limited number of such patients included in RCTs. To monitor safety and efficacy, patients receiving sotatercept should be treated in pulmonary hypertension centres and their management should include regular follow-up and appropriate examinations. To guide treatment strategy, the Task Force suggests performing RHC during follow-up in PAH patients who receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death, when therapeutic consequences are expected. The Task Force does not provide a recommendation for this question in PAH patients at low risk of death, due to the very low certainty of evidence. Conclusion: The ERS guidelines on the treatment of PAH provide an updated evidence-based framework for the optimal management of patients with PAH.
- 7 September 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2601178
European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension
Background: Pulmonary arterial hypertension (PAH) is a severe, progressive disease of the small pulmonary arteries. These guidelines provide updated evidence-based recommendations for the treatment of PAH focusing on the latest scientific evidence on sotatercept, an activin signalling inhibitor targeting a novel pathway for the treatment of PAH, and on the role of right heart catheterisation (RHC) in the management of PAH patients during follow-up. Methods: A European Respiratory Society (ERS) Task Force, comprising global experts, methodologists and a patient representative, developed these clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Four PICO (Patients, Intervention, Comparator, Outcomes) questions and one narrative question have been addressed. Recommendations: The Task Force recommends add-on treatment with sotatercept in PAH patients who already receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death during follow-up; this recommendation is based on a high certainty of evidence available from randomised controlled trials (RCTs). In PAH patients at low risk of death, the Task Force does not provide a recommendation due to the low certainty of evidence and the limited number of such patients included in RCTs. To monitor safety and efficacy, patients receiving sotatercept should be treated in pulmonary hypertension centres and their management should include regular follow-up and appropriate examinations. To guide treatment strategy, the Task Force suggests performing RHC during follow-up in PAH patients who receive PAH drugs and are at intermediate-low, intermediate-high or high risk of death, when therapeutic consequences are expected. The Task Force does not provide a recommendation for this question in PAH patients at low risk of death, due to the very low certainty of evidence. Conclusion: The ERS guidelines on the treatment of PAH provide an updated evidence-based framework for the optimal management of patients with PAH.
- Open Access
- 1 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (181) , 260159
Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes
Pulmonary arterial hypertension (PAH) with features of venous and/or capillary involvement, formerly pulmonary veno-occlusive disease (PVOD), represents a rare and severe subset of pulmonary hypertension. While PVOD is typically idiopathic, heritable or drug/toxin-induced, “PVOD-like” features have long been recognised in PAH associated with connective tissue diseases (CTDs), especially systemic sclerosis (SSc). This review synthesises the available evidence on this phenotype, integrating published data with an unreported cohort of 25 patients. Venular remodelling is a frequent histological finding in SSc-PAH lung explants, but high-resolution computed tomography (HRCT) signs of PVOD are inconsistently observed at PAH presentation, reflecting a progression of the lung vasculopathy and/or an unmasking effect of pulmonary vasodilators. Patients often exhibit major functional limitation, profound impairment in gas transfer and severe haemodynamic compromise. Assessing venular involvement in SSc-PAH poses unique challenges, due to possible lung fibrosis on HRCT and differential diagnosis with an occult post-capillary component. Despite the lack of robust evidence, PAH-approved therapies are commonly used, although with caution due to a high risk of pulmonary oedema with pulmonary vasodilators. As these patients also display significant arteriolar involvement, which can benefit from these drugs, dedicated treatment strategies warrant further investigation. Prognosis remains dismal, with a 5-year survival around 45–50%. Similar PVOD-like patterns have also anecdotally been reported in systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, Sjögren syndrome and inflammatory myopathies, with comparable features. Overall, PVOD-like disease in CTD-PAH constitutes a high-risk phenotype with unresolved pathogenic and management challenges, requiring refined patient stratification and improved therapeutic strategies.
- 1 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (181) , 260159
Open AccessPulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes
Pulmonary arterial hypertension (PAH) with features of venous and/or capillary involvement, formerly pulmonary veno-occlusive disease (PVOD), represents a rare and severe subset of pulmonary hypertension. While PVOD is typically idiopathic, heritable or drug/toxin-induced, “PVOD-like” features have long been recognised in PAH associated with connective tissue diseases (CTDs), especially systemic sclerosis (SSc). This review synthesises the available evidence on this phenotype, integrating published data with an unreported cohort of 25 patients. Venular remodelling is a frequent histological finding in SSc-PAH lung explants, but high-resolution computed tomography (HRCT) signs of PVOD are inconsistently observed at PAH presentation, reflecting a progression of the lung vasculopathy and/or an unmasking effect of pulmonary vasodilators. Patients often exhibit major functional limitation, profound impairment in gas transfer and severe haemodynamic compromise. Assessing venular involvement in SSc-PAH poses unique challenges, due to possible lung fibrosis on HRCT and differential diagnosis with an occult post-capillary component. Despite the lack of robust evidence, PAH-approved therapies are commonly used, although with caution due to a high risk of pulmonary oedema with pulmonary vasodilators. As these patients also display significant arteriolar involvement, which can benefit from these drugs, dedicated treatment strategies warrant further investigation. Prognosis remains dismal, with a 5-year survival around 45–50%. Similar PVOD-like patterns have also anecdotally been reported in systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, Sjögren syndrome and inflammatory myopathies, with comparable features. Overall, PVOD-like disease in CTD-PAH constitutes a high-risk phenotype with unresolved pathogenic and management challenges, requiring refined patient stratification and improved therapeutic strategies.
- Open Access
- 9 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6368
Increase in Alveolar Septal Width Is a Histological Predictor of Chronic Lung Allograft Dysfunction and Survival in Lung Transplant Recipients—A Longitudinal Study
Background: Chronic lung allograft dysfunction (CLAD) occurs in up to 50% of patients within the first five years after lung transplantation (LuTX) and represents the main complication and cause of death regarding this surgery. Alveolar septal widening in transbronchial biopsies has shown an association with acute humoral allograft rejection. We aimed to explore histological markers that could predict the development of CLAD before its clinical manifestation. Methods: We retrospectively analyzed transbronchial biopsies taken at three time points from 57 patients who underwent LuTX between February 2010 and July 2019, 26 of whom developed CLAD up to November 2022. The biopsies were analyzed by microscopic morphometry and quantitative reverse transcription PCR to identify predictors of CLAD. Results: CLAD development was associated with increased alveolar septal width (ASW) as early as the first year post-LuTX (5.46 ± 0.76 µm versus 4.59 ± 0.44 µm; p < 0.001). The ASW in later biopsy timepoints predicted survival in multivariate models (last timepoint: hazard ratio 1.885, 95% confidence interval 1.086–3.269). Collagen (COL1A1 and COL3A1) expression was significantly increased in samples from patients who developed CLAD compared with those who did not. The increase in ASW was paralleled by interstitial deposition of COL1A1 and COL3A1 and a decrease in both the carbon monoxide (DLCO) diffusing capacity of the lung and the DLCO/alveolar volume. Conclusions: We report a new histologic approach for early assessment of risk of CLAD in patients who have undergone LuTX. The ASW represents a pre-symptomatic, continuous, and widely distributed change within the lung parenchyma that is accessible to transbronchial biopsy.
- 9 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (18) , 6368
Open AccessIncrease in Alveolar Septal Width Is a Histological Predictor of Chronic Lung Allograft Dysfunction and Survival in Lung Transplant Recipients—A Longitudinal Study
Background: Chronic lung allograft dysfunction (CLAD) occurs in up to 50% of patients within the first five years after lung transplantation (LuTX) and represents the main complication and cause of death regarding this surgery. Alveolar septal widening in transbronchial biopsies has shown an association with acute humoral allograft rejection. We aimed to explore histological markers that could predict the development of CLAD before its clinical manifestation. Methods: We retrospectively analyzed transbronchial biopsies taken at three time points from 57 patients who underwent LuTX between February 2010 and July 2019, 26 of whom developed CLAD up to November 2022. The biopsies were analyzed by microscopic morphometry and quantitative reverse transcription PCR to identify predictors of CLAD. Results: CLAD development was associated with increased alveolar septal width (ASW) as early as the first year post-LuTX (5.46 ± 0.76 µm versus 4.59 ± 0.44 µm; p < 0.001). The ASW in later biopsy timepoints predicted survival in multivariate models (last timepoint: hazard ratio 1.885, 95% confidence interval 1.086–3.269). Collagen (COL1A1 and COL3A1) expression was significantly increased in samples from patients who developed CLAD compared with those who did not. The increase in ASW was paralleled by interstitial deposition of COL1A1 and COL3A1 and a decrease in both the carbon monoxide (DLCO) diffusing capacity of the lung and the DLCO/alveolar volume. Conclusions: We report a new histologic approach for early assessment of risk of CLAD in patients who have undergone LuTX. The ASW represents a pre-symptomatic, continuous, and widely distributed change within the lung parenchyma that is accessible to transbronchial biopsy.
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (8) , e017935
3D Reconstruction of Pulmonary Vascular Lesions in Chronic Thromboembolic Pulmonary Hypertension
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (8) , e017935
3D Reconstruction of Pulmonary Vascular Lesions in Chronic Thromboembolic Pulmonary Hypertension
- Top Cited PapersOpen Access
- 29 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (4) , 2401095
Pathology and pathobiology of pulmonary hypertension: current insights and future directions
In recent years, major advances have been made in the understanding of the cellular and molecular mechanisms driving pulmonary vascular remodelling in various forms of pulmonary hypertension, including pulmonary arterial hypertension, pulmonary hypertension associated with left heart disease, pulmonary hypertension associated with chronic lung disease and hypoxia, and chronic thromboembolic pulmonary hypertension. However, the survival rates for these different forms of pulmonary hypertension remain unsatisfactory, underscoring the crucial need to more effectively translate innovative scientific knowledge into healthcare interventions. In these proceedings of the 7th World Symposium on Pulmonary Hypertension, we delve into recent developments in the field of pathology and pathophysiology, prioritising them while questioning their relevance to different subsets of pulmonary hypertension. In addition, we explore how the latest omics and other technological advances can help us better and more rapidly understand the myriad basic mechanisms contributing to the initiation and progression of pulmonary vascular remodelling. Finally, we discuss strategies aimed at improving patient care, optimising drug development, and providing essential support to advance research in this field.
- 29 August 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (4) , 2401095
Top Cited PapersOpen AccessPathology and pathobiology of pulmonary hypertension: current insights and future directions
In recent years, major advances have been made in the understanding of the cellular and molecular mechanisms driving pulmonary vascular remodelling in various forms of pulmonary hypertension, including pulmonary arterial hypertension, pulmonary hypertension associated with left heart disease, pulmonary hypertension associated with chronic lung disease and hypoxia, and chronic thromboembolic pulmonary hypertension. However, the survival rates for these different forms of pulmonary hypertension remain unsatisfactory, underscoring the crucial need to more effectively translate innovative scientific knowledge into healthcare interventions. In these proceedings of the 7th World Symposium on Pulmonary Hypertension, we delve into recent developments in the field of pathology and pathophysiology, prioritising them while questioning their relevance to different subsets of pulmonary hypertension. In addition, we explore how the latest omics and other technological advances can help us better and more rapidly understand the myriad basic mechanisms contributing to the initiation and progression of pulmonary vascular remodelling. Finally, we discuss strategies aimed at improving patient care, optimising drug development, and providing essential support to advance research in this field.
- Open Access
- 29 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2827
A Novel Rat Model of Mild Pulmonary Hypertension Associated with Pulmonary Venous Congestion Induced by Left Pulmonary Vein Banding
Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common form of PH. In PH-LHD, changes in the pulmonary vasculature are assumed to be mainly caused by pulmonary venous congestion. However, the underlying mechanisms of this form of PH are poorly understood. We aimed to establish a model of PH associated with pulmonary venous congestion. Wistar–Kyoto rats underwent partial occlusion of the left pulmonary vein to induce pulmonary venous congestion or sham surgery and were assessed at various time points post-surgery (3, 6, 9, 12 weeks). In vivo cardiopulmonary phenotyping was performed by using echocardiography along with heart catheterization. Histomorphometry methods were used to assess pulmonary vascular remodeling (e.g., wall thickness, degree of muscularization). Left pulmonary vein banding (PVB) resulted in mildly elevated right ventricular systolic pressure and moderate right ventricular hypertrophy. In PVB rats, small- and medium-sized pulmonary vessels in the left lung were characterized by increased wall thickness and muscularization. Taken together, our data demonstrate that left PVB-induced pulmonary venous congestion is associated with pulmonary vascular remodeling and mild PH.
- 29 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2827
Open AccessA Novel Rat Model of Mild Pulmonary Hypertension Associated with Pulmonary Venous Congestion Induced by Left Pulmonary Vein Banding
Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common form of PH. In PH-LHD, changes in the pulmonary vasculature are assumed to be mainly caused by pulmonary venous congestion. However, the underlying mechanisms of this form of PH are poorly understood. We aimed to establish a model of PH associated with pulmonary venous congestion. Wistar–Kyoto rats underwent partial occlusion of the left pulmonary vein to induce pulmonary venous congestion or sham surgery and were assessed at various time points post-surgery (3, 6, 9, 12 weeks). In vivo cardiopulmonary phenotyping was performed by using echocardiography along with heart catheterization. Histomorphometry methods were used to assess pulmonary vascular remodeling (e.g., wall thickness, degree of muscularization). Left pulmonary vein banding (PVB) resulted in mildly elevated right ventricular systolic pressure and moderate right ventricular hypertrophy. In PVB rats, small- and medium-sized pulmonary vessels in the left lung were characterized by increased wall thickness and muscularization. Taken together, our data demonstrate that left PVB-induced pulmonary venous congestion is associated with pulmonary vascular remodeling and mild PH.
- Open Access
- 31 January 2024
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 33 (171) , 230144
Clinical–imaging–pathological correlation in pulmonary hypertension associated with left heart disease
Pulmonary hypertension (PH) is highly prevalent in patients with left heart disease (LHD) and negatively impacts prognosis. The most common causes of PH associated with LHD (PH-LHD) are left heart failure and valvular heart disease. In LHD, passive backward transmission of increased left-sided filling pressures leads to isolated post-capillary PH. Additional pulmonary vasoconstriction and remodelling lead to a higher vascular load and combined pre- and post-capillary PH. The increased afterload leads to right ventricular dysfunction and failure. Multimodality imaging of the heart plays a central role in the diagnostic work-up and follow-up of patients with PH-LHD. Echocardiography provides information about the estimated pulmonary artery pressure, morphology and function of the left and right side of the heart, and valvular abnormalities. Cardiac magnetic resonance imaging is the gold standard for volumetric measurements and provides myocardial tissue characterisation. Computed tomography of the thorax may show general features of PH and/or LHD and is helpful in excluding other PH causes. Histopathology reveals a spectrum of pre- and post-capillary vasculopathy, including intimal fibrosis, media smooth muscle cell hyperplasia, adventitial fibrosis and capillary congestion. In this paper, we provide an overview of clinical, imaging and histopathological findings in PH-LHD based on three clinical cases.
- 31 January 2024
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 33 (171) , 230144
Open AccessClinical–imaging–pathological correlation in pulmonary hypertension associated with left heart disease
Pulmonary hypertension (PH) is highly prevalent in patients with left heart disease (LHD) and negatively impacts prognosis. The most common causes of PH associated with LHD (PH-LHD) are left heart failure and valvular heart disease. In LHD, passive backward transmission of increased left-sided filling pressures leads to isolated post-capillary PH. Additional pulmonary vasoconstriction and remodelling lead to a higher vascular load and combined pre- and post-capillary PH. The increased afterload leads to right ventricular dysfunction and failure. Multimodality imaging of the heart plays a central role in the diagnostic work-up and follow-up of patients with PH-LHD. Echocardiography provides information about the estimated pulmonary artery pressure, morphology and function of the left and right side of the heart, and valvular abnormalities. Cardiac magnetic resonance imaging is the gold standard for volumetric measurements and provides myocardial tissue characterisation. Computed tomography of the thorax may show general features of PH and/or LHD and is helpful in excluding other PH causes. Histopathology reveals a spectrum of pre- and post-capillary vasculopathy, including intimal fibrosis, media smooth muscle cell hyperplasia, adventitial fibrosis and capillary congestion. In this paper, we provide an overview of clinical, imaging and histopathological findings in PH-LHD based on three clinical cases.
- Open Access
- 17 January 2024
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 33 (171) , 230156
Pulmonary veno-occlusive disease: illustrative cases and literature review
Pulmonary veno-occlusive disease (PVOD), also known as “pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement”, is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement, leading to increased pulmonary vascular resistance and right ventricular failure. Environmental risk factors have been associated with the development of PVOD, such as occupational exposure to organic solvents and chemotherapy, notably mitomycin. PVOD may also be associated with a mutation in theEIF2AK4gene in heritable forms of disease. Distinguishing PVOD from PAH is critical for guiding appropriate management. Chest computed tomography typically displays interlobular septal thickening, ground-glass opacities and mediastinal lymphadenopathy. Life-threatening pulmonary oedema is a complication of pulmonary vasodilator therapy that can occur with any class of PAH drugs in PVOD. Early referral to a lung transplant centre is essential due to the poor response to therapy when compared with other forms of PAH. Histopathological analysis of lung explants reveals microvascular remodelling with typical fibrous veno-occlusive lesions. This review covers the main features distinguishing PVOD from PAH and two clinical cases that illustrate the challenges of PVOD management.
- 17 January 2024
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 33 (171) , 230156
Open AccessPulmonary veno-occlusive disease: illustrative cases and literature review
Pulmonary veno-occlusive disease (PVOD), also known as “pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement”, is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement, leading to increased pulmonary vascular resistance and right ventricular failure. Environmental risk factors have been associated with the development of PVOD, such as occupational exposure to organic solvents and chemotherapy, notably mitomycin. PVOD may also be associated with a mutation in theEIF2AK4gene in heritable forms of disease. Distinguishing PVOD from PAH is critical for guiding appropriate management. Chest computed tomography typically displays interlobular septal thickening, ground-glass opacities and mediastinal lymphadenopathy. Life-threatening pulmonary oedema is a complication of pulmonary vasodilator therapy that can occur with any class of PAH drugs in PVOD. Early referral to a lung transplant centre is essential due to the poor response to therapy when compared with other forms of PAH. Histopathological analysis of lung explants reveals microvascular remodelling with typical fibrous veno-occlusive lesions. This review covers the main features distinguishing PVOD from PAH and two clinical cases that illustrate the challenges of PVOD management.
- Open Access
- 20 December 2023
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 32 (170) , 230237
From the microscopic to the macroscopic: clinical–radiological–pathological correlation in pulmonary hypertension
Tweetable abstract This editorial introduces a new European Respiratory Review series focusing on clinical, radiological and histopathological features in pulmonary hypertension.https://bit.ly/3RtiFVK
- 20 December 2023
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 32 (170) , 230237
Open AccessFrom the microscopic to the macroscopic: clinical–radiological–pathological correlation in pulmonary hypertension
Tweetable abstract This editorial introduces a new European Respiratory Review series focusing on clinical, radiological and histopathological features in pulmonary hypertension.https://bit.ly/3RtiFVK
- Open Access
- 20 December 2023
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 32 (170) , 230138
Clinical–radiological–pathological correlation in pulmonary arterial hypertension
Pulmonary hypertension (PH) is defined by the presence of a mean pulmonary arterial pressure >20 mmHg. Current guidelines describe five groups of PH with shared pathophysiological and clinical features. In this paper, the first of a series covering all five PH classification groups, the clinical, radiological and pathological features of pulmonary arterial hypertension (PAH) will be reviewed. PAH may develop in the presence of associated medical conditions or a family history, following exposure to certain medications or drugs, or may be idiopathic in nature. Although all forms of PAH share common histopathological features, the presence of certain pulmonary arterial abnormalities, such as plexiform lesions, and extent of co-existing pulmonary venous involvement differs between the different subgroups. Radiological investigations are key to diagnosing the correct form of PH and a systematic approach to interpretation, especially of computed tomography, is essential.
- 20 December 2023
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 32 (170) , 230138
Open AccessClinical–radiological–pathological correlation in pulmonary arterial hypertension
Pulmonary hypertension (PH) is defined by the presence of a mean pulmonary arterial pressure >20 mmHg. Current guidelines describe five groups of PH with shared pathophysiological and clinical features. In this paper, the first of a series covering all five PH classification groups, the clinical, radiological and pathological features of pulmonary arterial hypertension (PAH) will be reviewed. PAH may develop in the presence of associated medical conditions or a family history, following exposure to certain medications or drugs, or may be idiopathic in nature. Although all forms of PAH share common histopathological features, the presence of certain pulmonary arterial abnormalities, such as plexiform lesions, and extent of co-existing pulmonary venous involvement differs between the different subgroups. Radiological investigations are key to diagnosing the correct form of PH and a systematic approach to interpretation, especially of computed tomography, is essential.